Ron Metzger

Cooley advised early-stage venture capital firm RPM Ventures as the lead investor for Firefly Aerospace's oversubscribed $175 million Series D.

Cooley advised Cache DNA, a life sciences company revolutionizing biological sample and data storage infrastructure, on the close of its seed round.

Cooley advised the underwriters in IGM Biosciences’ $97.5 million public offering of 9,000,000 shares of non-voting common stock and 3,187,500 shares of voting common stock, each at the public offering price of $8.00 per share, as well as a $22.5 million concurrent private placement. IGM is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, autoimmune and inflammatory diseases, and infectious diseases. Denny Won, Kristin VanderPas and Charlie Kim led the Cooley team.

Cooley advised the underwriters on Zymeworks’ $115.0 million follow-on public offering of 11,035,000 common shares at a price to the public of $8.00 per share and pre-funded warrants to purchase 3,340,000 common shares at a price to the public of $7.9999 per pre-funded warrant. This includes 1,875,000 shares issued upon the exercise in full of the underwriters’ option to purchase additional shares. Zymeworks is a clinical-stage biopharmaceutical company developing and commercializing of next-generation multifunctional biotherapeutics. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.

Cooley advised the underwriters on IGM Biosciences’ $230 million follow-on offering of non-voting common stock and common stock.  J.P. Morgan, BofA Securities, Stifel and Guggenheim Securities acted as joint book-running managers for the offering. IGM Biosciences is a biotechnology company involved in the development of engineered IgM antibodies for the treatment of cancer patients. Partners Denny Won, Kristin VanderPas, and Charlie Kim led the Cooley team advising the underwriters.